Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma.

Published

Journal Article

BACKGROUND AND PURPOSE:The Head and Neck Imaging Reporting and Data System (NI-RADS) surveillance template for head and neck cancer includes a numeric assessment of suspicion for recurrence (1-4) for the primary site and neck. Category 1 indicates no evidence of recurrence; category 2, low suspicion of recurrence; category 3, high suspicion of recurrence; and category 4, known recurrence. Our purpose was to evaluate the performance of the NI-RADS scoring system to predict local and regional disease recurrence or persistence. MATERIALS AND METHODS:This study was classified as a quality-improvement project by the institutional review board. A retrospective database search yielded 500 consecutive cases interpreted using the NI-RADS template. Cases without a numeric score, non-squamous cell carcinoma primary tumors, and primary squamous cell carcinoma outside the head and neck were excluded. The electronic medical record was reviewed to determine the subsequent management, pathology results, and outcome of clinical and radiologic follow-up. RESULTS:A total of 318 scans and 618 targets (314 primary targets and 304 nodal targets) met the inclusion criteria. Among the 618 targets, 85.4% were scored NI-RADS 1; 9.4% were scored NI-RADS 2; and 5.2% were scored NI-RADS 3. The rates of positive disease were 3.79%, 17.2%, and 59.4% for each NI-RADS category, respectively. Univariate association analysis demonstrated a strong association between the NI-RADS score and ultimate disease recurrence, with P < .001 for primary and regional sites. CONCLUSIONS:The baseline performance of NI-RADS was good, demonstrating significant discrimination among the categories 1-3 for predicting disease.

Full Text

Duke Authors

Cited Authors

  • Krieger, DA; Hudgins, PA; Nayak, GK; Baugnon, KL; Corey, AS; Patel, MR; Beitler, JJ; Saba, NF; Liu, Y; Aiken, AH

Published Date

  • June 2017

Published In

Volume / Issue

  • 38 / 6

Start / End Page

  • 1193 - 1199

PubMed ID

  • 28364010

Pubmed Central ID

  • 28364010

Electronic International Standard Serial Number (EISSN)

  • 1936-959X

International Standard Serial Number (ISSN)

  • 0195-6108

Digital Object Identifier (DOI)

  • 10.3174/ajnr.a5157

Language

  • eng